RLYB Rasio cepet Rallybio Corp

The asset value for Rallybio Corporation (RLYB) tracked on the GURU.Markets chart is 28.92. Rallybio Corporation develops advanced therapies for rare fetal and blood pathologies and is currently funded by grants. While the company maintains research centers in Connecticut, production is synthesized by third-party CDMO facilities. The firm currently lacks pricing power as it awaits approval of its orphan drugs to transition to commercial sales.

The quick ratio measures a company's ability to instantly settle current liabilities using only cash and accounts receivable, excluding slow-moving inventories. An analysis of the quick ratio for Rallybio Corporation (RLYB) confirms financial autonomy during the implementation of joint research on rare pathologies, ensuring operational stability throughout the drug development period.